Interleukin-17 receptor type A (IL-17RA)

Interleukin-17 receptor type A (IL-17RA) is a ubiquitous transmembrane protein that serves as a common subunit for several heterodimeric receptors within the IL-17 receptor family, including those for IL-17A, IL-17F, and IL-17C (UniProt: Q96F46). It plays a pivotal role in the inflammatory response by recruiting the adapter protein ACT1, which triggers downstream signaling pathways like NF-kappaB and MAPK, leading to the production of pro-inflammatory cytokines and chemokines (PubMed: 22104523). Dysregulation of IL-17RA signaling is central to the pathogenesis of various autoimmune and inflammatory diseases, most notably psoriasis, psoriatic arthritis, and ankylosing spondylitis (StatPearls: NBK541071). Pharmacologically, IL-17RA is a validated therapeutic target; for instance, the monoclonal antibody brodalumab directly binds to and inhibits IL-17RA, effectively blocking the biological activity of multiple IL-17 isoforms (PubChem: CID 135313364). Therapeutic modulation of this receptor is highly effective in treating plaque psoriasis but requires monitoring for safety concerns such as increased susceptibility to fungal infections and potential psychiatric risks (FDA: Siliq Prescribing Information).

Other names

CD217IL17RAIL-17RCANDF5CDw217

Direct antagonism of the IL-17RA subunit to inhibit the signaling of IL-17A, IL-17F, IL-17A/F heterodimers, and IL-17E (IL-25).